Page 241 - Haematologica Vol. 109 - July 2024

ARTICLE - Prior cancers and risk of MGUS
Funding
The work of this study was supported by research funding from Landspítali-the National University Hospital of Iceland, the International Myeloma Foundation, the European Re- search Council, Rannís – the Icelandic Center for Research, the Swedish Cancer Society, and Thorsman’s Foundation. OL is supported by a Sylvester Comprehensive Cancer Center NCI core grant (P30 CA 240139), Riney Family Multiple My-
References
1. Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113(22):5412-5417.
2. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood. 2003;102(10):3759-3764.
3. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362-1369.
4. Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet. 2010;375(9727):1721-1728.
5. Canzian F, Piredda C, Macauda A, et al. A polygenic risk score for multiple myeloma risk prediction. Eur J Hum Genet. 2022;30(4):474-479.
6. Thordardottir M, Lindqvist EK, Lund SH, et al. Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study. Blood Adv. 2017;1(24):2186-2192.
7. Landgren O, Shim YK, Michalek J, et al. Agent orange exposure and monoclonal gammopathy of undetermined significance: an Operation Ranch Hand veteran cohort study. JAMA Oncol. 2015;1(8):1061-1068.
8. Zheng X, Li X, Wang M, et al. Second primary malignancies among cancer patients. Ann Transl Med. 2020;8(10):638.
9. van den Boogaard WMC, Komninos DSJ, Vermeij WP. Chemotherapy side-effects: not all DNA damage is equal. Cancers (Basel). 2022;14(3):627.
10. Lopes R, Caetano J, Ferreira B, Barahona F, Carneiro EA, João C. The immune microenvironment in multiple myeloma: friend or foe? Cancers (Basel). 2021;13(4):625.
11. Langseth ØO, Myklebust TÅ, Johannesen TB, Hjertner Ø, Waage A. Patterns of previous and secondary malignancies in patients with multiple myeloma. Eur J Haematol. 2021;106(4):529-536.
12. Hanzis C, Ojha RP, Hunter Z, et al. Associated malignancies in patients with Waldenström’s macroglobulinemia and their kin. Clin Lymphoma Myeloma Leuk. 2011;11(1):88-92.
13. van den Broek EC, Liu L, Posthuma EFM, Janssen-Heijnen MLG, Coebergh JWW, Soerjomataram I. Increased risk of chronic lymphocytic leukaemia among cancer survivors in the Netherlands: increased detection, causal factors or both? Ann
S. Rögnvaldsson et al. eloma Research Program Fund, Tow Foundation, Myeloma
Solutions Fund, and Perelman Family Foundation.
Data-sharing statement
Current approvals do not allow for sharing of the underlying study data. However, data may be shared with other inves- tigators pending the review of the iStopMM investigators and the Icelandic Scientific Ethics Committee.
Hematol. 2014;93(1):157-162.
14. Sasieni PD, Shelton J, Ormiston-Smith N, Thomson CS, Silcocks
PB. What is the lifetime risk of developing cancer?: the effect of adjusting for multiple primaries. Br J Cancer. 2011;105(3):460-465.
15. Rögnvaldsson S, Love TJ, Thorsteinsdottir S, et al. Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J. 2021;11(5):94.
16. Kristinsson SY, Björkholm M, Goldin LR, McMaster ML, Turesson I, Landgren O. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/ Waldenström macroglobulinemia patients: a population-based study in Sweden. Blood. 2008;112(8):3052-3056.
17. Sigurdardottir LG, Jonasson JG, Stefansdottir S, et al. Data quality at the Icelandic Cancer Registry: comparability, validity, timeliness and completeness. Acta Oncol. 2012;51(7):880-889.
18. Smith Jervelund S, De Montgomery CJ. Nordic registry data: value, validity and future. Scand J Public Health. 2020;48(1):1-4.
19. Turesson I, Linet MS, Björkholm M, et al. Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer. 2007;121(10):2260-2266.
20. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29(5):573-582.
21. Shah UA, Rögnvaldsson S, Derkach A, et al. Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls. Haematologica. 2022;107(1):284.
22. Sigurbergsdóttir AÝ, Rögnvaldsson S, Thorsteinsdottir S, et al. Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) study. Haematologica. 2023;108(12):3392-3398.
23. Bedard PL, Hyman DM, Davids MS, Siu LL. Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet. 2020;395(10229):1078-1088.
24. Yu JX, Hubbard-Lucey VM, Tang J. Immuno-oncology drug development goes global. Nat Rev Drug Discov. 2019;18(12):899-900.
Haematologica | 109 July 2024
2255